로딩 중…
StockDiggingStockDigging

ICON Public Limited Company

ICLR· NASDAQ
IEIE
$169.68-2.45%
2026-09-17

Financials

Valuation Metrics

ICON Public Limited Company's Market Cap is $13.20B. At end of 2025 it was $14.10B. Ranked #774 of 3,121 in US market (top 25%), #242 of 1,463 on NASDAQ (top 17%), #49 of 205 in Health Care Equipment & Services (top 24%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$13.20B
Revenue$8.25B
Net Income$329M
Total Assets$16.40B
Net Assets$9.38B
Employees40,200
Value
P/E40.13x
P/B1.41x
P/S1.60x
EV/EBITDA12.66x
FCF Yield10.20%
Profitability
ROE3.51%
ROA2.01%
Op. Margin10.15%
Revenue Growth2.01%
Earnings Growth-58.59%
Financial Health
Debt Ratio74.88%
Total Debt$3.49B
FCF$1.35B
Cash$928M
Current Ratio0.95x
Net Debt/EBITDA2.06x
Performance
1Y Return-3.16%
1M Return1.57%
From 52W High-16.79%
1Y MDD-60.54%
Trading
Volume1,152,317 shares
Trading Value$198M
Per Share
EPS$4.23
BPS$120.59

Company Info

CEO Barry Balfe
Employees 40,200
HQ Dublin, IE

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.